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ABSTRACT 
 
Title 
Pattern of practice of Radical Radiation Therapy of Oropharyngeal Cancer: A retrospective 
review from January 2009 to December 2012. 
 
Background  
Radiation therapy is a highly effective method of treating oropharyngeal carcinoma, either as 
a single modality treatment with concurrent chemotherapy or as an adjuvant treatment after 
surgical resection. There exists an association with human papillomavirus (HPV) and 
oropharyngeal cancer, dividing oropharyngeal carcinoma into HPV positive oropharyngeal 
carcinoma and HPV negative oropharyngeal carcinoma. Overall survival has been analysed 
in these two groups and have been shown to be 80-95% for HPV positive oropharyngeal 
carcinomas and 57-62% in HPV negative subgroup at 3 years respectively. This retrospective 
review was intended to analyse patient response to treatment, overall survival, local disease 
free survival and the difference between HPV positive oropharyngeal carcinoma and HPV 
negative oropharyngeal carcinoma at Charlotte Maxeke Johannesburg Academic Hospital: 
Department of Radiation Oncology. 
 
Patients and methods 
A retrospective descriptive study was conducted on patients having received radical radiation 
therapy, with or without chemotherapy, from January 2009 to December 2012 with a 
histologically confirmed diagnosis of squamous cell carcinoma involving oropharyngeal sites 
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only.  The information obtained from records of forty-eight patients was captured on the 
prescribed data sheets designed for this study. 
 
Results 
Forty-eight eligible patients were accrued within this retrospective study. The median age of 
the patient group was 56 years (range 32-78) and comprised of 10 females and 38 males. The 
performance status was mainly Eastern Cooperative Oncology Group (ECOG) 1 (83%).  The 
radiation therapy dose was within the range 60-70Gy, with majority patients completing 70 
Gy (65%). Concurrent chemoradiation was given in 59% of patient group (28 patients). The 
most common site being the base of tongue (60%), followed by tonsil (36%), soft palate (2%) 
and posterior pharyngeal wall (2%). Eighty five percent of patients were stage IV 
oropharyngeal carcinoma. Only 6% of patients were tested for HPV-DNA PCR, and all were 
HPV positive. A total of 79% patients had a positive smoking history and 50% consumed 
alcohol regularly.  Fifty six percent of patients tested negative for HIV, 14.6% tested positive 
for HIV and 29.3% had unknown HIV status. 
At the time of the analyses (March 2014) only 7 (15%) of patients were alive. The 2 year 
overall survival was 13%, the local disease free survival at 2 years was 59%.  None of the 
prognostic factors were predictive of overall survival using univariate and multivariate 
analysis. 
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Conclusion 
Majority of patients present in stage IV lesions with commonest sites of involvement being 
Base of Tongue.  The local disease free survival of 2 years was 59% and the overall survival 
of 15%.  There was no impact of prognostic factors studied on overall survival. 
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1.0 INTRODUCTION 
 
1.1 Background 
A subset of tumours involving the mucosa of the base of tongue (BOT), palatine 
tonsils, soft palate and the posterior pharyngeal wall collectively make up 
oropharyngeal cancers[1,2]. The proximal boundary is at the edge of the hard palate 
and it is distally bound by valleculae and hyoid bone as illustrated in Figure 1.1[3] 
Figure 1.1 The anatomy of the oropharynx [3] 
 
 
Worldwide squamous cell carcinoma (SCC) of the oropharynx is the twenty-
second most common cancer [4], with an annual incidence of 8-10 per 100000 
population [5]. 
Approximately 300-350 new cancers of the head and neck region are seen in the 
Department of Radiation Oncology at the Charlotte Maxeke Johannesburg 
Academic Hospital every year. Oropharyngeal cancers comprise approximately 
2% of newly diagnosed head and neck cancers per annum.  
HPV-related rates rose rapidly among the white men born since the mid-1940s, 
tripling among those aged 25-44 and recently surpassing the black male rate. [6]. 
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1.2 Aetiology  
Figure 1.2 Mechanism of action of HPV on cell cycle regulation [7] 
 
 
More than 80% of oropharyngeal cancers have been associated with HPV [8-11]. 
This virus is generally associated with changes in sexual practice such as 
increased number of sexual partners including oral sex partners, young age first 
sexual intercourse, human immunodeficiency virus infection (HIV) and repeated 
sexually transmitted diseases. HPV is a small non-enveloped Deoxyribonucleic 
acid (DNA) virus, which has high affinity to affect the skin and mucous 
membrane in humans. There are over 100 subtypes of HPV; the type associated 
with oropharyngeal carcinoma most notably is HPV type 16.  The HPV contains 
two oncogenes E6 and E7 that are key factors in the carcinogenesis process as 
illustrated in Figure 1.2 [11, 12]. These oncogenes inactivate two important tumour 
suppressor genes, P53 and Retinoblastoma (RB), which regulate cell cycle growth 
and proliferation [11, 12]. Degradation (P53) and inactivation (RB) of tumour 
suppressor genes lead to genomic instability and ultimately HPV induced 
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oropharyngeal carcinoma [11, 12]. Modern trend of HPV positive oropharyngeal 
cancers are in the white male, younger age, higher socio-economic status, who 
demonstrate little or no history of smoking and or alcohol use.  
 
Historically, tobacco smoking and alcohol use are long known well defined risk 
factors for HPV negative oropharyngeal cancers. These two substances either 
individually or together (synergistic effect) contribute to the field cancerization 
effect in the oropharynx. This cancerization effect is not seen in HPV positive 
oropharyngeal carcinoma. Cigarette smoking contains mutagens and carcinogens, 
which may act as promoters in the cancer process.  In a separate pooled analysis, 
low intensity tobacco use over a longer period yielded a greater risk factor than 
high intensity use over a shortened period [13]. With alcohol use, this was reversed, 
with high intensity and shorter duration of its use-increased risk of acquiring 
cancer [13]. The consumption of alcohol and cigarette smoking has declined over 
the past several decades, which allowed a decrease risk of head and neck cancers 
and subsequently an expected decrease in HPV negative oropharyngeal cancers [14, 
15]
.  Poor oral hygiene coupled with a low fruit and vegetable diets were associated 
with the development of oropharyngeal cancers.  
 
HPV positive and HPV negative oropharyngeal carcinomas have different clinical, 
pathological, and molecular features that distinguish them from each other.  
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Table 1.1 Difference between HPV-positive and HPV-negative SCC [1, 12] 
 
 
 
1.3 Natural History 
Oropharyngeal cancers develop in the posterior aspect of the mouth. The subsites 
are the tonsillar complex, BOT, soft palate and the pharyngeal wall. 
HPV-positive tumours, typically present with smaller primary tumours and a more 
advanced lymph-node stage, with the lymph node often having a cystic 
appearance [1, 18, 19].  
 
HPV-negative cancers have variable presentation.  Tumours at the BOT present at 
a more advanced stage, with a high propensity to nodal spread and are often 
poorly differentiated [20]. Thirty to fifty percent of patients will present with 
Characteristic  HPV-positive HPV-negative 
Age Younger Older 
Socio-economic status High Low 
Anatomic site Tonsil and BOT All site 
Risk Factors Sexual behaviour Alcohol and tobacco use 
Histology  Non-keratinized, 
basaloid 
Keratinized 
Molecular/pathological 
change [16,17] 
TP53 wild type,           
p16 positive,                       
No Epidermal Growth 
Factor Receptor (EGFR) 
over over-expressed. 
TP53 mutated 
High EGFR expression 
Survival Improved Worse 
Second primary 
tumours/field 
cancerization 
Negative Positive 
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uncontrolled loco-regional cancers and will progress to the development of distant 
metastasis [21]. Common presenting symptoms are persistent sore throat and 
dysphagia. 
 
A large proportion of oropharyngeal cancers occur in the tonsillar complex, 
initially asymptomatic, with more severe late symptoms of otalgia, bleeding, 
decreased mobility of oral tongue and trismus. These findings are suggestive of 
advanced disease.  
Pharyngeal wall and soft palate tumours are relatively rare tumours. 
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Figure 1.3 Lymph node levels of the Neck [22] 
 
 
The primary route of spread for oropharyngeal carcinomas are through direct 
extension, lymphatic spread and less commonly haematogenous metastases [20].  
The most common lymph-node metastasis in oropharynx is ipsilateral level II [20] 
as illustrated in Figure 1.3[22]. Lymph-node metastasis is related to primary tumour 
size and location.  Nodal staging for oropharyngeal cancer is illustrated in 
Appendix 8.7 
 
Distant metastatic spread is relatively uncommon, with lung parenchyma being 
the most common site, followed by osseous and hepatic metastases [20]. 
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1.4 Preventative measures 
Recently, interest has been growing for the development of a vaccine due to viral 
causation in the development of oropharyngeal cancers. Vaccines targeting the 
high-risk subtype of HPV (types 16 and 18) and the low risk type (type 6 and 11) 
are being developed. Two HPV vaccines have been approved by the Food and 
Drug Administration (FDA) for clinical use. Both are available in South Africa, 
Cervarix (bivalent vaccine, directed against HPV type 16 and 18) and Gardasil 
(Quadrivalent vaccine Merck, directed against HPV type 6, 11, 16 and 18) [23].  
Other malignancies related to HPV namely cervical cancer for which the HPV 
vaccine was approved for the use in South Africa in 2008 [23].  
 
In USA, the Advisory committee on Immunization Practises recommends the 
routine vaccination of all females aged 11-12 years; the vaccination of 
unvaccinated women between 13 years – 26 years (South Africa 9-26 years) and 
since 2011 the routine vaccination of boys [24,25]. 
 
It is envisaged that this vaccination will decrease the rate of HPV related 
premalignant lesions and cancers (including oropharyngeal cancers).   
 
1.5 Staging 
Staging of oropharyngeal carcinoma is based on the American Joint Committee on 
Cancer (AJCC)/Union for International Cancer Control (UICC) system. This 
clinical staging was based on available history, physical examination, endoscopic, 
and radiographic data.  
Staging of oropharyngeal carcinomas are described in detail in Appendix 8.1. 
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1.6  Management of oropharyngeal cancers  
The main aim for management of oropharyngeal cancer is the preservation of 
organ function with minimal toxicity.  Most patients presenting at Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH) have advanced disease and 
are not candidates for surgery.   
 
Based on the AJCC staging system patients are put into different stages ranging 
from, locally confined disease (stage I and II tumours) which are considered early 
stage disease, and locally advanced disease (stage III and IV) non-metastatic 
disease. This staging helps guide treatment decisions. 
For all subsites, early stage disease are generally treated with a single modality, 
either radiation therapy or surgery.  Locally advanced disease generally requires a 
multi-modality approach. This can be either:  
a) Surgery followed by radiation therapy with or without chemotherapy 
based on pathological risk factors or  
b) Radiation therapy given with chemotherapy.  
 
Radiation can be given alone, as a definitive therapy, without chemotherapy due 
to medical co-morbidities, low CD4 count in Human immunodeficiency virus 
(HIV) positive patient or patient refusal.  
 
The most common site and stage of oropharyngeal cancer seen was the BOT, 
stage IV. The management of stage IV BOT at CMJAH is concurrent 
chemoradiation. These patients are planned on virtual simulation. The planning 
process includes positioning of patient, placement of field borders, beam 
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arrangements with beam modifiers and dose prescription. Typical planning of a 
patient are as described below. 
 
POSITIONING: 
Patient’s simulation and treat position is supine, in a mask and head on a headrest. 
The spine is straightened. The shoulders are immobilized by straps. The chin 
extended.  The patient is CT scanned with 5mm slices from the base of skull to 
level of the carina. 
 
BEAM ARRANGEMENTS: 
Radiation therapy is delivered via a three field technique; through isocentric 
opposed-lateral fields (large fields) matched to a lower neck portal (anterior neck 
field).  
       
  Large fields (bilateral face and neck) are lateral parallel opposed photon fields to                                 
treat the primary tumour and the upper neck nodes. 
 
Multi-leaf collimators are used to shape the field borders depending on the site 
lesion, and block out some of the oral cavity and the base of skull, including 
brain.  
This field is treated up to 40Gy. Then an off cord field is planned, here all the 
field borders are the same except for the posterior border that moves completely 
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off the spinal cord, to around the anterior 1/3rd vertebral body for all lesion except  
post pharyngeal wall where it extends past 1/3rd vertebra. This is done to make 
sure the dose to the spinal cord is within radiation tolerance of the spinal cord.  
Off cord are treated to a further 30Gy. 
 
Wedge pair fields (beam modifiers) are used in the large fields and in the off cord 
fields. The anterior neck field is usually used for irradiating the mid, lower neck 
and supraclavicular nodes. The superior border is matched to the inferior border 
of the lateral portals at the skin using asymmetric jaws. Inferior border is 2 cm 
below the clavicles. The lateral borders include the medial two-thirds of the 
clavicles.   
 
A midline lead block is used from the beginning of treatment of the anterior neck 
field to block out spine. The block extends 1cm above the superior border of the 
field and 1cm below the inferior border of the field for divergence and to prevent 
leakage. The width of the block is 2cm. 
 
RIGHT AND LEFT POSTERIOR NECK FIELDS: 
A clinical mark is done to the patient while on the treatment bed. Electrons are 
used to treat this. A strip of skin is left to prevent oedema.  The depths of the 
lymph nodes on each side are used to calculate the energy of the electron beam.  
The large fields, off-cords and anterior neck fields are treated with 6MV photons.  
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1.7 Prognosis 
Several studies have shown an over-all survival rate of 80-95% for HPV positive 
patients compared to 57-62% for HPV negative subgroup of oropharyngeal 
cancer at 3 years respectively [26].  
The rate of curability in these patients depends on the extent of the primary 
tumour (stage and specific site).   BOT cancer has a local control rate of 
approximately 85% for early lesions [3]. 
Tonsil carcinoma in a retrospective review displayed survival rates of 89% (stage 
1), 91% (stage II), 79% (stage III) and 52% (stage IV) [27].  
In a retrospective review with SCC of the soft palate, the over-all survival was 
80% at 2 years and dropped to 67% at 5 years [28]. 
Definitive radiation therapy given to SCC of pharyngeal wall resulted in cause 
specific survival rates at 89 % (stage I), 88 %( stage II), 44% (stage III) and 34 % 
(stage IV) [29]. 
 
1.8 Rationale for this study 
At the CMJAH, approximately 80-85% of patients present with advanced disease 
and in a poor general condition (anaemia, low serum protein, low ECOG and poor 
general health). These patients are offered palliative radiation therapy and best 
supportive care.  
 
The remaining 15-20% of patients are suitable for radical/curative treatment, 
either by surgery followed by adjuvant radiation therapy with or without 
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chemotherapy or definitive radiation therapy with or without chemotherapy. The 
radiation therapy dose ranges from 60-70Gy in 30-35 fractions given 5 days a 
week once daily treatments. The chemotherapy schedule used in the department of 
Radiation Oncology at CMJAH is Cisplatin 70mg/m2 given every 21 days.  
 
The objective of this study was to assess if the patients presented at CMJAH were 
able to receive the internationally recommended doses of radiation and 
chemotherapy and if the survival rates match those presented internationally.  
 
With the emergence of HPV as a causative agent in oropharyngeal cancers and its 
excellent response to treatment, an additional outcome of this study was to assess 
a similar outcome and percentage positivity for HPV. 
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2.0 LITERATURE REVIEW 
 
2.1  Radiation therapy treatment  
Radiation therapy is a highly effective treatment of oropharyngeal cancers, as a 
single modality, with concurrent chemotherapy or as an adjuvant post-surgery. 
It has emerged as the standard of care in definitive treatment of oropharyngeal 
carcinoma [30]. 
 
There has been significant evolution with radiation therapy in oropharyngeal 
cancers from two-dimensional treatment planning (2D), where standard treatment 
field delineation was based on bony landmarks, to more conformal techniques that 
based treatment planning on CT scan and a three-dimensional radiation therapy 
(3DCRT) to more modern intensity modulated radiation therapy (IMRT).  
Much of the data regarding radiation therapy comes from trials using 2D 
conventional treatment. Optimal doses and fractionation schedules have largely 
been tested. 
 
To best understand total dose and fractionation scheme, The European 
Organization for Research and Treatment of Cancer (EORTC) evaluated benefits 
of hyper fractionation (80.5Gy using 1.15Gy/fraction twice daily) compared with 
conventional fractionation (70Gy using 1,8Gy/fraction once daily) in the EORTC 
22791 trail. The patients treated with hyper fractionation had improved loco-
regional control (5 years, 59% vs. 40%; P=0,02). Additionally there was a trend 
toward improved over-all survival (p=0,08) particularly in stage III [31]. 
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To further investigate optimal fractionation scheme, the Radiation Therapy 
Oncology Group (RTOG) enrolled patients on the RTOG 90-03, which, compared 
four different fractionation regimens: 
a) Conventional fractionation (70Gy using 2Gy/fraction once daily) 
b) Spilt course accelerated fractionation (67.2Gy using 1.6Gy/fraction twice daily 
with a two week break after 38,4Gy) 
c) Concomitant boost fractionation (72Gy using 1.8Gy/fraction in the mornings 
and 1.5Gy/fraction boost as a second daily treatment during the last 12days) 
d) Hyper fractionation (81.6Gy using 1.2Gy/fraction twice-daily). 
 
Of the 1073 patients enrolled, 60% had oropharyngeal cancer. Patients treated 
with pure hyper fractionation and concomitant boost technique (c & d) had 
improved loco regional control and a trend towards improved Disease Free 
Survival (DFS) (37,6% vs. 31,7% and 39,3% vs. 31,7%), compared to the other 
two arms (conventional and split course); there were no differences in over-all 
survival. These improvements were associated with increased acute (mucositis 
and oesophagitis) and late toxicities (radiation myelitis) in all three accelerated 
arms [32]. 
 
     A study done in the Danish Head and Neck Cancer Study Group compared the 
use of standard 5 fractions/week fractionation and accelerated 6 fractions/week 
fractionation; patients were treated to a dose of 66-68Gy at 2Gy/fraction. Patients 
treated with 6 fractions/week had improved 5 year rates of loco regional control 
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(70% vs. 60%; p=0,0005) and disease specific survival (73% vs. 66%; p=0,01), 
however there was no difference in overall survival [33].  
 
From the studies mentioned above, altered fractionation schedule has a significant 
benefit in SCC, but with associated severe toxicities when delivered with 
conventional fractionation. 
 
With advances in radiation therapy, a more conformal way of delivering radiation 
therapy with increased sparing of normal tissue and the prevention on late 
complications saw the development of IMRT. Several recent trials have been 
performed with IMRT, looking at loco regional control, functional 
outcome/toxicity and its role when given with chemotherapy. Data from these 
studies showed excellent loco regional control rates and improved toxicity 
outcomes as compared with conventional methods [34, 35]. The most notable 
outcome with IMRT was statistically significant reduction in xerostomia and 
improvements in quality of life [36].  
 
At CMJAH, oropharyngeal cancers are treated with virtual simulation. This is 
similar to 2.5D planning and treatment where CT scan is being used for planning. 
Radiation doses used for this radical treatment range from 60Gy-70Gy in 30-35 
fractions.  
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2.2  Chemotherapy 
For locally advanced oropharyngeal cancers, concurrent chemoradiation is the 
standard of care, which is based on results of the meta-analysis of Chemotherapy 
in Head and Neck cancers (MACH-HC). Data was collected on greater than 
16000 patients with head and neck cancers treated from 1965 to 2000 as part of 
87 randomized trials; individual patient data were assembled and analysed with 
regards to the benefit of chemotherapy (neoadjuvant, concurrent and adjuvant). 
The common primary site was oropharynx (37% of all patients). The analysis 
showed a significant benefit in over-all survival with the use of chemotherapy, 
with a corresponding hazard ratio of death of 0,88 (p < 0,0001) and an absolute 
benefit of chemotherapy at 5 years of 4,5%. The timing of chemotherapy was also 
analysed, and concurrent chemotherapy was found to be superior to neoadjuvant 
or adjuvant chemotherapy [37]. 
      
Cisplatin based chemotherapy demonstrated most significant benefit when given 
concurrently, due to its potent radiosensitizing effect. 
 
Chemoradiation has emerged as standard of care in locally advanced SCC cancer 
of head and neck; however, it is associated with increased toxicity. An analysis of 
three RTOG trials (RTOG 91-11, 97-03 and 99-14) Machtay and colleagues [38] 
noted that 43% of patients treated with concurrent chemoradiation developed 
severe late toxicities. The French Groupe d’ Oncologies Radiotherapie Tete et 
Cou (GORTEC) trial [39] patients treated with concurrent chemoradiation had a 
rate of severe late toxicity (grade 3 and 4) of 56% vs. 30% in radiation only arm 
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This data has shown an increased efficacy with concurrent chemotherapy, at the 
cost of increased acute and late toxicities. 
 
2.3  Surgery 
The historical approach to surgery for oropharyngeal carcinoma involved 
extensive surgery at the cost of poor cosmesis and quality of life due to the 
functional impairment. Majority of the patients that had surgery done in the study 
group would have ultimately required radiation with or without chemotherapy. 
Indications for post-operative radiation therapy are close margins, T3 or T4 
primary cancer, perineural invasion, multiple positive lymph nodes, and 
lymphovascular space invasion. Indications for postoperative chemotherapy are 
positive margins and extra capsular extension.  
 
There has been an evolution in surgical techniques with the development of 
computer-assisted surgical technique [40].  
 
Although, improvement of surgical techniques have been made the future of 
treatment of oropharyngeal cancer is still in radiation and chemoradiation. 
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3.0 PATIENTS AND METHODS 
 
This analysis was a retrospective descriptive study involving the review of patient case 
records. It was undertaken at the Department of Radiation Oncology at CMJAH. The 
Protocol for the study was approved by the Postgraduate Committee of the Department of 
Radiation Sciences, Faculty of Health Sciences, University of Witwatersrand (Appendix 
8.3). The ethical clearance was obtained from the Human Research Ethics Committee at 
the University of Witwatersrand (Clearance certificate number M140234) (Appendix 
8.5). 
 
3.1 Patient characteristics 
A retrospective study of patients with the diagnosis of SCC of the oropharynx was 
conducted at CMJAH. Ninety oropharyngeal cancer patients received treatment at 
the head and neck clinic over a 4-year period (1 January 2009 to 31 December 
2012). Of this patient group, only 48 patients were candidates for radical/curative 
radiation therapy and therefore the analysis was limited to these 48 patients. 
Permission to view these files was obtained from the Chief Executive Officer 
(CEO) of CMJAH (Appendix 8.3).  
All patients fulfilled the following inclusion criteria: 
• Oropharyngeal cancers (Tonsil, BOT, Soft palate, Pharyngeal wall) 
only. 
• Age of patients >18 years old. 
• SCC histology only. 
• Patients accepted for radical/curative treatment. 
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Exclusion Criteria: 
• Other head and neck tumour sites (Nasopharynx, Hypopharynx, and 
oral cavity). 
• Distant metastasis. 
• Histology other than Squamous carcinoma 
The following information was, obtained from the files and captured on a data 
capture sheet/performa (Appendix 8.6): 
• Demographics: Age, gender and race. 
• Date of first consultation 
• Site of tumour with the oropharynx 
• Histological subtype 
• Stage of disease 
• HIV status 
• HPV status 
• Smoking history  
• Alcohol history 
• ECOG status (Appendix 8.2) 
• Date of start and completion of treatment 
• Management: dose of radiation therapy received, chemotherapy history 
• Response to treatment 
• Status patient last seen 
This data were entered into a Microsoft Excel 2013 spreadsheet. 
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Table 3.1 Patient and tumour characteristics 
 
Characteristics 
 
Number patients 
(n=48) 
Age Group  
            31-40 years 
            41-50 years 
            51-60 years 
            61-70 years 
            71-80 years 
Mean    
Median 
 
 
2 (4%) 
8 (17%) 
22 (46%) 
12 (25%) 
4 (8%) 
56.23 years 
                         57 years 
Tumour site 
BOT 
Tonsil 
Soft palate 
Pharyngeal wall 
 
29 (60%) 
17 (36%) 
1 (2%) 
1(2%) 
Tumour stage  
Stage I 
Stage II 
Stage III 
Stage IV 
 
0 
1 (2%) 
6 (13%) 
41 (85%) 
HIV status 
Positive 
Negative 
Unknown 
 
7 (14,6%) 
27 (56,3%) 
14 (29,2%) 
HPV status 
Positive 
Negative 
Unknown 
 
3 (6%) 
0 
45 (94%) 
Smoking  
Yes 
No 
Ex-smoker 
 
38 (79%) 
4 (8%) 
6 (13%) 
Alcohol 
           Yes 
            No 
           Ex-alcohol consumer 
 
24 (50%) 
11 (23%) 
13 (27%) 
 
ECOG performance status 
0 
1 
2 
3 
 
0 (0%) 
40 (83%) 
7 (15%) 
1 (2%) 
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All 48 patients received radical radiation therapy with doses ranging from 60-
70Gy. Some patients received Cisplatin 70mg/m2 concurrent chemoradiation. 
Patient selection for concurrent chemoradiation was based on the tumour stage, 
ECOG status, the creatinine clearance rate, and the overall general condition of 
patient.  
These patients were monitored during treatment as well as routinely post-
treatment.  
 
Table 3.2 Treatment characteristics 
 
Characteristic 
 
 
Number of patients 
(n=48) 
Radiation therapy 
60Gy 
62Gy 
64Gy 
66Gy 
68Gy 
70Gy 
 
1 (2%) 
1 (2%) 
1 (2%) 
12 (25%) 
2 (4%) 
31 (65%) 
Chemotherapy 
            None 
            Unknown 
            1 cycles 
2 cycles 
 
19 (40%) 
1 (2%) 
16 (33%) 
12 (25%) 
 
 
Table 3.1 outlines the patient and tumour characteristics whereas table 3.2 shows 
patient treatment characteristics. 
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3.2 Statistical analysis 
Statistical analysis was done using SPSS 21 package, a computerised statistical 
program. The mean values of the parameters such as age were compared using 
paired sample t-tests. The local control and disease free survival was calculated 
from the 1st day of treatment to the 1st day of local failure. 
The over-all survival calculated from the 1st day of treatment to the date of death 
or last day of follow up, using the Kaplan Meier analysis and long rank test.  
Multivariate analysis using the Cox regression model was performed to assess the 
significance of various parameters such as median/mean age, sex, stage of disease, 
site of lesion on the disease free and overall survival. 
 
3.3 Beam Arrangements 
Radiation therapy is delivered via a three field technique; through isocentric 
opposed-lateral fields (large fields) matched to a lower neck portal (anterior neck 
field). 
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4.0 RESULTS 
 
A total of 48 patients were retrospectively analysed in this study, of which 38 were males 
and 10 were female. The race/ethinicty was not analysed in this study. The median age 
was 56 years (range: 32 – 78 years). 
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Figure 4.1 Patient age distribution 
 
As illustrated in Figure 4.1, majority of patients in this study were betweenn the ages of 50-
65 years. 
The bulk of patients in this study had good ECOG performance score of 1 (83%) and 2 
(15%). Only one patient had an ECOG performance score of 3 and was included in this 
radical treatment group of patients.  79% of the patients were current smokers and 50% of 
patients regularly consumed alcohol.  
Gender had no prognostic significance when analyzed on both multivariate and univariate 
analysis. 
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Figure 4.2 Patient cancer stage distributions 
 
The patients in this study were staged according to the AJCC/UICC system. They were 
grouped according to their tumour extent (T), lymph-node status (N) and presence or absence 
of distant metastasis (M). Most of the patients in the analysis had locally advanced primary 
tumour, with nodal disease, categorizing them as IV shown in Figure 4.2. 
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Figure 4.3 Patient Lesion sites 
 
As illustrated in figure 4.3 different subsites were treated. The most common presenting site 
of disease was the BOT, followed by the tonsil. Since most of the patients presented with 
locally advanced disease and due to the close proximity of these sites, the tumour sometimes 
involved more than on site. Treatment fields for radiation therapy included the entire 
oropharynx, with a margin for microscopic extension.  
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Figure 4.4 Patient dose schedules 
 
All the patients received radical radiation therapy doses (range 60-70 Gy) shown in figure 
4.4. The majority completed treatment in 7 weeks, with a small fraction having split 
treatment due to acute skin toxicities. Fifty-eight percent of patients received concurrent 
chemotherapy, with 16 (33%) receiving one cycle and 12 (25%) receiving two cycles.  
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Figure 4.5 Overall survival graph for patient group with lost to follow-up patients 
added to dead patients 
 
 
When the lost to follow up was added to the dead patients and the alive censored, the overall 
survival at 2 years was 13 % Figure 4.5. 
At the time of this analysis, 7 (15%) patients were alive, 20 (42%) were dead and 21 (43%) 
lost to follow up. The overall survival at 2 years was 50 %, with the lost to follow-up added 
to the alive patients.   
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Figure 4.6 Patient local disease free survival results 
 
The local disease free survival at 2 years was 59%, as illustrated in Figure 4.6. Local 
treatment failure occurred in 13 (27%) patients.  
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Table 4.1 Tabulated p-values results by using multivariate and univariate method 
Prognostic factors 
p-values 
multivariate 
p-value 
univariate  
Age >= 55 years 26 patients 
        <   55 years 22 patients 0.744  1,00 
ECOG 0,218 1,00 
Smoking 0,889 1,00 
Sex 0,799 1,00 
HIV status 0,603 1,00 
AJCC stage 0,605 1,00 
Site 0,389 1,00 
Chemotherapy 0,714 1,00 
 
On multivariate and univariate analysis using Cox regression analysis, none of the prognostic 
factors were predictive for over-all survival as shown in table 4.1. 
 
Late toxicities in the patient group could not be analysed due to the no documentation of at 
follow evaluations.  
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5.0 DISCUSSION 
 
In advanced oropharyngeal carcinoma, the main goal of therapy was local disease control, 
organ function preservation and improving the patient’s quality of life. Oropharyngeal 
cancer affects speech, swallowing, degustation, and psychological well-being. All these 
factors must be considered when managing this cancer. 
 
Combination modality treatment, with concurrent chemoradiation has shown to improve 
local control rates and over-all survival in patients with locally advanced stage III-IV 
oropharyngeal cancer [30, 37, 41].  In the recent years, there has been improvement in the 
prognosis of oropharyngeal carcinoma due to advances in radiation therapy delivery, 
addition of concurrent chemotherapy and the high prevalence of HPV virus [26, 42]. 
 
Numerous studies have shown that HPV positive oropharyngeal carcinoma has a higher 
overall survival rate than HPV negative oropharyngeal cancer, and a better prognosis 
regardless of the treatment modalities used [26,43]. HPV status was independently 
associated with improved outcomes. The Eastern Cooperative Oncology Group, Trans-
Tasman Radiation Oncology Group, Radiation Therapy Oncology Group and Danish 
Head and Neck Cancer study groups have shown over-all survival rates between 62%-
95% (HPV positive oropharyngeal cancers) and 26%-77% (HPV negative oropharyngeal 
cancers).   
 
Most oropharyngeal carcinomas are diagnosed at advanced stages and with a higher 
incidence of lymph-node metastasis, most likely related to the rich lymphatic supply of 
the oropharynx.  
 32 
 
The primary endpoint of this retrospective review was to assess response to treatment, 
overall survival, disease free survival and the difference between HPV positive and 
negative oropharyngeal carcinoma with patients having received radical treatment. The 
treatment modalities used were radical dose radiation therapy (60-70Gy), with or without 
concurrent chemotherapy (cisplatin 70mg/m2).  
 
These treatment modalities did not show an improvement in over-all survival or the 
disease free survival. At the time of analysis (March 2014), only 7 (15%) patients were 
alive, 20 (42%) patients were dead and 21 (44%) patients were lost to follow-up.   The 
overall survival at 2 years was 50%, when all lost to follow-up and alive was censored.  
Overall survival was 13% when only alive patients were censored. These results had no 
correlation with current literature, demonstrating a poorer overall survival. The HPV-
DNA Polymerase chain reaction (PCR) test was only performed routinely in three 
patients out of the forty-eight making it difficult to analyse the difference between the 
HPV positive and negative patients. The local disease free survival at the 2nd year was 
59%, which correlated with the current literature. The log rank univariate and multivariate 
analysis of prognostic factors were not predictive for over-all survival. 
 
  An analysis conducted by Ang et al. (2011) reported overall survival on stage III and IV 
positive and negative oropharyngeal carcinoma. 3 year overall survival rate was 82,4% 
(HPV positive) compared to 57,1% (HPV negative). Loco-regional failure remains 
common in HPV negative tumours, with 15-35% of locally advanced disease developing 
local recurrence within 3 years [26].  
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GORTEC reported a multi-institutional randomized prospective trial comparing radiation 
therapy plus concurrent chemotherapy with radiation alone in patients with stage III and 
IV oropharyngeal cancer. The three year overall survival was 51% vs. 31%, 3 year 
disease free survival was 42% vs. 20% and loco-regional control 66% vs. 42% 
respectively [30]. 
 
A retrospective review conducted at the Department of Radiation Oncology at the 
University of Texas M.D Anderson Cancer Center evaluated patients with locally 
advanced oropharyngeal cancers (stage III and IVb SCC) treated with modern therapy 
approaches from 2000-2007. This review demonstrated relatively high survival rates in 
the locally advanced oropharyngeal cancer treated with non-surgical techniques.  The 5-
year actuarial overall survival, recurrence-free survival and local-regional control rates 
for the entire cohort were 78%, 77%, and 87% respectively. The study also concluded 
increasing T-stage and smoking were associated with higher rates of local-regional 
recurrence and poor survival [43]. 
 
An important aspect of this retrospective review was a large number of patients that were 
lost to follow up (21 patients-44%).  Another significant factor was the bulk of patients 
having received treatment, formed part of the low socio-economic populous of the greater 
Johannesburg area. Majority of patients were lost to follow-up. This factor has 
highlighted the lack of comprehensive patient biographic information accrual which must 
be developed and recorded in an effective database.  Patients must provide at the 
minimum three different contact numbers as well as next of kin before treatment can be 
initiated.  Designated officials must follow-up with patients absconding from 
appointments. Additional attempts need to be made through social workers and the Home 
 34 
 
Affairs Department of South Africa (ID checks, death registration etc.).  Proper control of 
patients can lead to better management of early recurrence, poor nutritional status and 
treatment related toxicities. The initial counselling of patients must be intensive and 
comprehensive.  The importance of treatment and follow up care must be explained and 
patients must be reassured and helped if complications arise during treatment.  
The limitations of this retrospective analysis were sample size per treatment group, poor 
recording at pre-treatment evaluation and at follow-up in most patients, and a large 
number of patients were lost to follow-up (21 patients 44%). As only 3 patients had HPV-
DNA PCR tests done, comparison between HPV positive and negative oropharyngeal 
cancer could not be done.  
Late toxicities in this patient group could not be analysed due to the poor follow up 
documentation. Gender had no prognostic significance when analyzed on both 
multivariate and univariate analysis. 
Further suggestions for improvement of patient follow-up are: 
• Have a designated person for patient follow-up (research co-ordinator/ State entity 
/ Out-patient-department oncology nurse or social worker). 
• Proper document check at record filing office at the time of registration (Identity 
document check). 
• Regular training of new and updating knowledge of existing staff regarding the 
importance of high quality record keeping. 
• Full residential information and contact details. 
• Follow-up records should be checked at least once every six months. 
• Patient must provide at least 3 reachable telephone numbers. 
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6.0 CONCLUSION 
 
In this retrospective pattern of care analysis for radical radiation therapy with or without 
concurrent chemotherapy for oropharyngeal carcinoma, found that the mortality rate at 2 
years was significantly high. Majority of patients were lost to follow up with unknown 
reasons. Intensive and comprehensive pre-counselling is vital for the success treatment 
and follow up outcomes. Only three patients in this study were routinely tested for HPV 
virus in an HPV causing cancer.  
 
Majority of patients present in stage IV lesions with commonest sites of involvement 
being Base of Tongue.  The local disease free survival of 2 years was 59% and the overall 
survival of 15%.  There was no impact of prognostic factors studied on overall survival. 
 Literature suggests better outcomes in patients with HPV positive oropharyngeal cancer. 
The routine testing of HPV-DNA PCR should be implemented so as to distinguish 
between the two groups. There are ongoing trials looking at reducing treatment doses in 
the HPV positive, which can ultimately reduce treatment toxicities.  
 
Advanced radiation therapy techniques have emerged in the last decade. 3DCRT delivery 
of treatment was limited to traditional geometric fields until the development of IMRT. 
IMRT is considered standard of care in most countries for patients with oropharyngeal 
carcinoma, because of its significant tissue sparing effect leading to improved quality of 
life. Although, improvement of surgical techniques have been made the future of 
treatment of oropharyngeal cancer is still in radiation and chemoradiation. 
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Clinicians must tailor treatment of patients, based on age, ECOG status, co-morbidities, 
HPV status and compliance of patients. Optimal management ultimately depends on a 
multidisciplinary evaluation.  
 
Implementation of these strategies may allow for comparable overall survival, disease 
free survival and compliance data to international data.  
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8.0 APPENDICES 
 
8.1 Stages of Oropharyngeal Carcinoma 
The following stages are used for oropharyngeal cancer [43]: 
Stage 0 (Carcinoma in Situ) 
In stage 0, abnormal cells are found in the lining of the oropharynx. These abnormal 
cells may become cancer and spread into nearby normal tissue. Stage 0 is also called 
carcinoma in situ.   
 
 The different T-stages of oropharyngeal cancer are shown above [22]. 
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Pea, peanut, walnut, and lime show tumour sizes shown above [45]. 
Stage I 
In stage I, cancer has formed and is 2 centimeters or smaller and is found in the 
oropharynx only. 
Stage II 
In stage II, the cancer is larger than 2 centimeters but not larger than 4 centimeters 
and is found in the oropharynx only. 
Stage III 
In stage III, the cancer is either: 
• 4 centimeters or smaller; cancer has spread to one lymph node on the same side 
of the neck as the tumour and the lymph node is 3 centimeters or smaller; or  
• Larger than 4 centimeters or has spread to the epiglottis (the flap that covers the 
trachea during swallowing). Cancer may have spread to one lymph node on the 
same side of the neck as the tumour and the lymph node is 3 centimeters or 
smaller.  
Stage IV 
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Stage IV is divided into stage IVA, IVB, and IVC as follows: 
• In stage IVA, cancer:  
o Has spread to the larynx, front part of the roof of the mouth, lower jaw, or 
muscles that move the tongue or are used for chewing. Cancer may have 
spread to one lymph node on the same side of the neck as the tumour and 
the lymph node is 3 centimetres or smaller; or 
o Has spread to one lymph node on the same side of the neck as the tumour 
(the lymph node is larger than 3 centimetres but not larger than 6 
centimetres) or to more than one lymph node anywhere in the neck (the 
lymph nodes are 6 centimetres or smaller), and one of the following is 
true:  
 Tumour in the oropharynx is any size and may have spread to the 
epiglottis (the flap that covers the trachea during swallowing); or 
 Tumour has spread to the larynx, front part of the roof of the 
mouth, lower jaw, or muscles that move the tongue or are used for 
chewing. 
• In stage IVB, the tumour:  
o Surrounds the carotid artery or has spread to the muscle that opens the jaw, 
the bone attached to the muscles that move the jaw, nasopharynx, or base 
of the skull. Cancer may have spread to one or more lymph nodes which 
can be any size; or 
o May be any size and has spread to one or more lymph nodes that are larger 
than 6 centimeters. 
• In stage IVC, the tumour may be any size and has spread beyond the oropharynx 
to other parts of the body, such as the lung, bone, or liver. 
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8.2 ECOG Performance Status Scale[46] 
 
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance 
without restriction 
1 Restricted in physically strenuous activity but ambulatory and 
able to carry out work of a light or sedentary nature, e.g., light 
house work, office work 
2 Ambulatory and capable of all selfcare but unable to carry out 
any work activities. Up and about more than 50% of waking 
hours 
3 Capable of only limited selfcare, confined to bed or chair more 
than 50% of waking hours 
4 Completely disabled. Cannot carry on any selfcare. Totally 
confined to bed or chair 
5 Dead 
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8.3 Protocol Study Approval 
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8.4 Masters of Medicine Approval 
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8.5. Ethics Clearance Certificate 
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8.6 Patient Data Capture Form/Performa 
PERFORMA FOR OROPHARYNGEAL CANCERS 
CODE NUMBER: 
 
DATE OF REGISTRATION: 
 
DXT NUMBER: 
 
SITE OF OROPHARYNGEAL CANCER 
• 1 = TONSILLAR COMPLEX  
• 2 = BASE OF TONGUE 
• 3 = SOFT PALATE 
• 4 = PHARYNGEAL WALLS 
 
HIV STATUS 
• 1 = POSITIVE  
• 2 = NEGATIVE 
 
HPV STATUS 
• 1 = POSITIVE 
• 2 = NEGATIVE 
• 3 = NOT TESTED 
 
HISTOLOGY SUBTYPE 
• 1 = SQUAMOUS CELL CARCINOMA 
 
ECOG STATUS:  
• 1 = ECOG1 
• 2 = ECOG2 
• 3 = ECOG3 
 
SMOKING 
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• 1 = NEVER SMOKED 
• 2 = EX-SMOKER 
• 3 = CURRENT SMOKER 
 
ALCOHOL USE: 
• 1 = NEVER DRANK 
• 2 = EX-DRINKER 
• 3 = DRINKER 
 
TNM STAGE:  
 
RADIATION DOSE RECEIVED: 
• 1 = 60 Gy 
• 2 = 66 Gy 
• 3 = 70 Gy 
 
CONCOMITANT CHEMOTHERAPY: 
• 1 = YES 
• 2 = NO 
 
NO OF CYCLES CHEMOTHERAPY RECEIVED: 
 
START DATE TREATMENT: 
 
COMPLETION DATE OF THERAPY: 
 
DATE OF PROGRESSION: 
 
DATE OF DEATH: 
 
DISEASE FREE SURVIVAL (MONTHS): 
 
OVER-ALL SURVIVAL (MONTHS): 
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8.7 Nodal Staging for Oropharyngeal Cancer 
 
 
Figure 8.7.1 Nodal Staging [47] 
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Figure 8.7.2 Nodal Staging [47] 
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Figure 8.7.3 Nodal Staging [47] 
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Figure 8.7.4 Nodal Staging [47] 
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Figure 8.7.5 Nodal Staging [47] 
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8.8 Plagiarism Report 
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